Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis

NCT06517875 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

68

Enrollment

INDUSTRY

Sponsor class

Conditions

Primary Myelofibrosis
Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis

Interventions

DRUG: Momelotinib
DRUG: Luspatercept

Sponsor

GlaxoSmithKline